Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Merck to Present New Data on Keytruda Next Week

By Merck | December 1, 2016

New Keytruda (pembrolizumab) data to be presented at 17th World Conference on Lung Cancer highlight research across the spectrum of thoracic malignancies.

Merck announced that new data investigating the use of Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, across multiple thoracic malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer and malignant pleural mesothelioma, will be presented at the 17th World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Vienna, Austria, Dec. 4-7. An abstract evaluating quality of life outcomes in first-line NSCLC will be included on Wednesday, Dec. 7.

“Based on the meaningful results already obtained in studies evaluating the use of Keytruda in certain patients with PD-L1 positive non-small cell lung cancer, we have asked whether similar benefits might be associated with Keytruda use in treating other intrathoracic malignancies, including small cell lung cancer and malignant pleural mesothelioma,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “We look forward to sharing our recent findings with the scientific community as we seek to help patients facing these difficult diseases.”

The Keytruda (pembrolizumab) clinical development program includes more than 30 tumor types in more than 360 clinical trials, including over 200 trials that combine Keytruda with other cancer treatments. Merck has an extensive research program in NSCLC and is currently advancing multiple registration-enabling studies with Keytruda as monotherapy and in combination.

Keytruda is a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. Keytruda blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. It is administered as an intravenous infusion over 30 minutes every three weeks for the approved indications. For injection, Keytruda is supplied in a 100 mg single use vial.

Additional meeting information and full abstracts are available on the WCLC meeting website.

(Source: Business Wire)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE